Generalized necrobiotic xanthogranuloma successfully treated with lenalidomide.
Necrobiotic xanthogranuloma (NXG) presents a therapeutic challenge to clinicians. Generalized NXG has limited treatment options. A patient presented to the authors with generalized NXG associated with monoclonal gammopathy of unknown significance (MGUS), a plasma cell dyscrasia considered to be a precursor to multiple myeloma. The patient was treated with lenalidomide, a derivative of thalidomide with efficacy in treatment of multiple myeloma. Resolution of paraproteinemia was associated with resolution of NXG.
Silapunt
Sirunya
S
Department of Dermatology, University of Texas Medical School at Houston, Houston, TX, USA.
Chon
Susan Y
SY
D000368:Aged; D000369:Aged, 80 and over; D003907:Dexamethasone / Q000627:therapeutic use; D006099:Granuloma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D000077269:Lenalidomide; D008297:Male; D008998:Monoclonal Gammopathy of Undetermined Significance / Q000188:drug therapy; D017441:Necrobiotic Disorders / Q000188:drug therapy* / Q000473:pathology; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D013792:Thalidomide; D003907:Dexamethasone; D000077269:Lenalidomide